Articles
Most Favored Nation Price Controls Disfavor Patients
Market Institute President Charles Sauer warns that the Trump administration’s expansion of Most Favored Nation (MFN) drug pricing risks trading America’s pharmaceutical leadership for uncertain short-term savings. In a new piece for RealClearMarkets, Sauer examines Read more…
